Clinical Trials
18 trialsNCT04079712 2026-04-13
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03223155 2026-03-04
COSINR
University of Chicago
Phase 1 Active not recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03670056 2025-07-20
Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
Yale University
Phase 2 Active not recruiting
NCT02922764 2025-03-26
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
Phase 1 Completed
NCT03043599 2024-12-20
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT02046733 2024-11-08
STIMULI
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03752398 2024-07-05
DUET-3
Xencor, Inc.
Phase 1 Completed
NCT04610658 2024-04-02
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT03083691 2024-01-17
BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
Lung Cancer Group Cologne
Phase 2 Completed
NCT03406715 2023-03-30
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT01840579 2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03026166 2020-07-17
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
AbbVie
Phase 1/2 Terminated
NCT01450761 2020-07-08
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Bristol-Myers Squibb
Phase 3 Completed
NCT00527735 2018-07-18
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
Bristol-Myers Squibb
Phase 2 Completed
NCT01331525 2016-04-14
ICE
University Hospital Southampton NHS Foundation Trust
Phase 2 Completed